+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

A new HDAC inhibitor cinnamoylphenazine shows antitumor activity in association with intensive macropinocytosis

A new HDAC inhibitor cinnamoylphenazine shows antitumor activity in association with intensive macropinocytosis

Oncotarget 8(9): 14748-14758

Previous studies have shown that intensive macropinocytosis occurs in cancer cells and neutral red (NR) is noted for its capability to enter into the cell massively through a process mimetic to macropinocytosis. In addition, trans-cinnamic acid (tCA) has been found to be an inhibitor of histone deacetylase (HDAC). In the present study, cinnamoylphenazine (CA-PZ) that consists of NR and tCA moieties was synthesized and evaluated. As shown, CA-PZ massively entered into colon carcinoma HT-29 cells and pancreatic carcinoma MIA PaCa-2 cells and this entry was blocked by 5-(N-ethyl-N-isopropyl) amiloride (EIPA, an inhibitor of macropinocytosis), indicating a macropinocytosis-mediated uptake. Furthermore, CA-PZ markedly increased the protein expression levels of acetyl-H3, acetyl-H4 and p21 in HT-29 cells and MIA PaCa-2 cells. CA-PZ significantly inhibited the growth of colon carcinoma HT-29 and pancreatic carcinoma MIA PaCa-2 xenografts. By in vivo imaging, CA-PZ displayed prominent accumulation in the tumor xenografts. The study indicates that the newly synthesized CA-PZ acts as an HDAC inhibitor in association with intensive macropinocytosis-mediated intracellular delivery in cancer cells. The use of neutral red for preparation of chimeric molecules with the attribute of macropinocytosis-mediated intracellular delivery might open an alternative way for development of HDAC inhibitors.

Please choose payment method:

(PDF emailed within 1 workday: $29.90)

Accession: 059362597

Download citation: RISBibTeXText

PMID: 28107195

Related references

Development of N-hydroxycinnamamide-based HDAC inhibitors with improved HDAC inhibitory activity and in vitro antitumor activity. Bioorganic and Medicinal Chemistry 25(9): 2666-2675, 2017

Biphenyl-4-yl-acrylohydroxamic acids: Identification of a novel indolyl-substituted HDAC inhibitor with antitumor activity. European Journal of Medicinal Chemistry 112: 99, 2016

Preclinical antitumor activity of ST7612AA1: a new oral thiol-based histone deacetylase (HDAC) inhibitor. Oncotarget 6(8): 5735-5748, 2015

Novel Golgi Inhibitor Shows Potent Antitumor Activity. 2012

Heat shock protein inhibitor shows antitumor activity. Journal of the National Cancer Institute 94(16): 1194-1195, 2002

A Selective Inhibitor Shows Antitumor Activity in ALK-Rearranged NSCLC. Cancer Discovery 3(6): 601-601, 2013

Evaluation of the antitumor effects of BPR1J-340, a potent and selective FLT3 inhibitor, alone or in combination with an HDAC inhibitor, vorinostat, in AML cancer. Plos one 9(1): E83160, 2014

The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activity. Cancer Research 69(15): 6208-6215, 2009

Oral administration of the pimelic diphenylamide HDAC inhibitor HDACi 4b is unsuitable for chronic inhibition of HDAC activity in the CNS in vivo. Plos one 7(9): E44498, 2012

Pan-PI-3 kinase inhibitor SF1126 shows antitumor and antiangiogenic activity in renal cell carcinoma. Cancer ChemoTherapy and Pharmacology 75(3): 595-608, 2015

The selective VEGFR1-3 inhibitor axitinib (AG-013736) shows antitumor activity in human neuroblastoma xenografts. International Journal of Cancer 128(11): 2748-2758, 2011

A new small-molecule Aurora B inhibitor shows antitumor activity in human cancer cell lines. Molecular Biology Reports 42(2): 517-524, 2015

MK1775, a selective Wee1 inhibitor, shows single-agent antitumor activity against sarcoma cells. Molecular Cancer Therapeutics 11(1): 174-182, 2012

MK-5108, a highly selective Aurora-A kinase inhibitor, shows antitumor activity alone and in combination with docetaxel. Molecular Cancer Therapeutics 9(1): 157-166, 2010

A Novel Covalent mTOR Inhibitor, DHM25, Shows in Vivo Antitumor Activity against Triple-Negative Breast Cancer Cells. Journal of Medicinal Chemistry 58(16): 6559-6573, 2015